Modus Therapeutics
Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 -39.9x EV/EBITDA | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | SEK28.3m | Post IPO Equity |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | - | 60 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | 50 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Modus Therapeutics is a Swedish biotechnology company focused on developing sevuparin, a novel therapeutic for treating diseases with high unmet medical needs. The company primarily targets conditions such as sepsis and septic shock, which are severe and often fatal. Modus Therapeutics operates in the healthcare and pharmaceutical market, collaborating with institutions like Imperial College London to advance clinical research. The business model revolves around the development and commercialization of sevuparin, aiming to bring this innovative treatment to market through clinical trials and regulatory approvals. Revenue is generated through partnerships, grants, and eventual sales of the approved drug. The company serves healthcare providers, hospitals, and patients suffering from critical conditions.
Keywords: sevuparin, sepsis, septic shock, severe malaria, biotech, clinical trials, pharmaceutical, healthcare, innovation, Sweden.